What happened in this Health story?

An FDA advisory panel recommended approving Grail's multicancer blood test despite a failed 140,000-person NHS trial that showed no reduction in late-stage cancer diagnoses, a decision that would trigger mandatory Medicare coverage under a law passed earlier this year.

What is a key fact in this story? (1)

**Grail's NHS trial** enrolled 140,000 people but failed to show a reduction in late-stage cancer — the surrogate endpoint investigators chose instead of cancer death.

What is a key fact in this story? (2)

**An FDA advisory panel** recommended approving Grail's multicancer blood test despite the negative trial result, leaving the agency itself to make the final call.

📎 SkimNews has covered FDA 83+ times · see the file →

FDA Urged to Reject Grail Cancer Test After Failed Trial — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-06

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

Grail's NHS trial enrolled 140,000 people but failed to show a reduction in late-stage cancer — the surrogate endpoint investigators chose instead of cancer death.
An FDA advisory panel recommended approving Grail's multicancer blood test despite the negative trial result, leaving the agency itself to make the final call.
The Medicare Multi-Cancer Early Detection Screening Coverage Act, signed earlier this year, would mandate Medicare coverage of such tests upon FDA approval, bypassing the U.S. Preventive Services Task Force.
Grail has been sued by its own investors twice (2024 and 2026), and former UK Prime Minister David Cameron served as a paid adviser during the company's NHS partnership.
Annual screening of all Americans 50 and older would cost an estimated $60–$100 billion per year, based on a population of 120 million and a per-test cost between $500 (the Cologuard Medicare benchmark) and $949 (Grail's list price).
The National Cancer Institute is preparing a major randomized trial using cancer death as the endpoint, which the author warns could be undermined if patients can already get multicancer screening covered by insurance.
The author's core argument is that earlier detection doesn't equal fewer deaths, citing ovarian cancer screening as precedent: fewer late-stage cases, no change in mortality.

Why it matters: If the FDA approves Grail's test, Medicare is legally obligated to cover it, and the author estimates $60–$100 billion in annual costs to screen 120 million Americans 50 and older — while the more rigorous NCI trial that could actually answer whether the test saves lives may be undermined by early coverage.